Neuberger Berman Group
RAPT

Neuberger Berman Group’s RAPT Therapeutics RAPT Stock Holding History

Neuberger Berman Group’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,829
Closed -$1.13M – 1966
2021
Q4 		$1.13M Sell
3,829
-8
-0.2% -$2.14K ﹤0.01% 1333
2021
Q3 		$951K Buy
+3,837
New +$1.01M ﹤0.01% 1322

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Neuberger Berman Group's RAPT Position: Q1 2022 in Review

Neuberger Berman Group sold out of RAPT Therapeutics (RAPT) in Q1 2022, closing a stake of 3,829 shares — an estimated $1.13M sold.

Neuberger Berman Group first reported a position in RAPT in Q3 2021 and held it in 2 quarters. The position peaked at $1.13M in Q4 2021. 85 funds tracked by Wall St. Rank hold RAPT as of Q1 2022.

  • Neuberger Berman Group reported no remaining RAPT Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Neuberger Berman Group sold 3,829 RAPT Therapeutics shares in Q1 2022, an estimated $1.13M.
  • Neuberger Berman Group first reported a position in RAPT Therapeutics in Q3 2021 and held it in 2 quarters.
  • Neuberger Berman Group's RAPT Therapeutics position peaked at $1.13M in Q4 2021.
  • 85 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2022.

Based on Neuberger Berman Group's 13F filing for Q1 2022, filed 13 May 2022.